Skip to main content

Epigenomics to Continue Cancer Biomarker Collaboration with AstraZeneca

NEW YORK, May 16 (GenomeWeb News) - Epigenomics said today that it will continue a collaboration with AstraZeneca to identify DNA methylation biomarker candidates for use in AstraZeneca's oncology programs.

 

Epigenomics said that it successfully completed a biomarker-discovery study with AstraZeneca last year, and that it will now test the potential of those markers to predict response to EGFR inhibitors such as AstraZeneca's Iressa in a panel of preclinical cancer models.

 

Under the terms of the agreement, Epigenomics will receive R&D fees and can participate in the development of any pharmacodiagnostic products resulting from the collaboration.

 

Further financial details were not disclosed.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.